FindTrial
Sign In

A multicenter, randomized, double-blind, placebo-based parallel-controlled clinical study of Bushen Huoxue Decoction for treatment of coronary heart disease in stable angina pectoris with kidney deficiency and blood stasis syndrome

A randomized, double-blind, placebo parallel-controlled clinical study of the intervention of Bushen Huoxue Decoction in the intervention of kidney deficiency and blood stasis syndrome in coronary heart disease

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300070977
Enrollment
Unknown
Registered
2023-04-27
Start date
2023-05-01
Completion date
Unknown
Last updated
2023-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary heart disease in stable angina pectoris

Interventions

Experimental group:Bushen Huoxue Granules + Conventional Western Medicine
Control group:Placebo Granules + conventional Western medicine

Sponsors

Guang'anmen Hospital, China Academy of Chinese Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Follow the diagnostic criteria for stable angina pectoris of coronary heart disease; 2. Patients who diagnosed with kidney deficiency and blood stasis syndrome by TCM syndromes; 3. Patients aged between 40 and 80 years; 4. Patients who voluntarily sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Severe valvular heart disease, severe neurosis, menopausal syndrome, hyperthyroidism, cervical spondylosis, biliary heart disease, stomach and esophageal reflux and other non-coronary heart disease caused by chest pain; 2. Poor hypertension control (under drug control, blood pressure >=160/100mmHg at rest and occasionally within a week), severe cardiopulmonary insufficiency (EF<35%), severe arrhythmia (rapid atrial fibrillation, atrial flutter, paroxysmal ventricular tachycardia,atrioventricular block of type II and above, complete bundle branch block); 3. Complicated with serious primary diseases such as heart, brain, liver, kidney, hematopoietic system, (hepatic function ALT or AST value ?1.5 times the upper limit of normal, patients with abnormal renal function), insulin-dependent type 2 diabetes; 4. Patients with depression or anxiety; 5.Pregnant or lactating women; 6. Patients with malignant tumors; 7. Patients with allergies and allergies to test drug components; 8. Patients with poor compliance and low possibility of follow-up; 9. Participants in other clinical trials within the past month; 10. Other major diseases or factors that interfere with the completion of the trial or affect the interpretation of the results.

Design outcomes

Primary

MeasureTime frame
The effect of coronary heart disease and angina pectoris;—

Secondary

MeasureTime frame
The effect of TCM Syndromes of coronary heart disease and angina pectoris;Stop and decrease of nitroglycerin;ECG efficacy;Seattle Angina Questionnaiire;Blood lipid efficacy;Cardiovascular endpoint;Safety evaluation;—

Countries

China

Contacts

Public ContactJie Wang

Guang’anmen Hospital,China Academy of TCM,Beijing

wangjie0103@126.com+86 10 88001238

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 6, 2026